Th1-Polarizing Capacity of Clinical-Grade Dendritic Cells Is Triggered by Ribomunyl but Is Compromised by PGE2
- 1 September 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 28 (5) , 480-487
Abstract
The maturation state of (monocyte-derived) dendritic cells (DCs) determines the type of T-cell response. Currently, several maturation cocktails are used in clinical trials, most commonly a cocktail of TNF-α, PGE2, IL-1β, and IL-6. The authors studied DC phenotype and functional ability to stimulate TH1 responses after maturation with different cocktails employing clinically approved agents. DCs were stimulated with the microbial agent Ribomunyl combined with IFN-γ and various inflammatory cytokine cocktails: TNF-α/IL-1β/IFN-γ and TNF-α/PGE2 combined with monocyte-conditioned medium (MCM) or IL-1β/IL-6. Regardless of the maturation cocktail used, all DCs possessed the characteristic phenotype of mature, migratory DCs (high expression of CD40, CD80, CD83, CD86, CCR7, MHC class I and MHC class II). Ribomunyl/IFN-γ matured DCs produced high IL-12p70 levels, whereas other maturation stimuli did not. Even more striking, restimulation of Ribomunyl IFN-γ mDCs with CD40-activating antibody reactivated IL-12p70 production. No IL-12p70 could be detected when DCs were stimulated with TNF-α/PGE2 combined with MCM or IL-1β/IL-6, presumably by suppression by PGE2. Restimulation of these DCs with CD40-activating antibody failed to activate IL-12p70 production. Moreover, low levels of IL-10 were observed, possibly indicating inhibition of TH1-cell responses. Indeed, T cells stimulated with these DCs produced high levels of type 2 cytokine IL-5 and outgrowth of CD4+CD25+ T cells. This study shows that DC maturation with cytokine cocktails different from those most commonly used could be beneficial for immunotherapy trials in cancer patients.Keywords
This publication has 20 references indexed in Scilit:
- The IL-12 Family of Heterodimeric CytokinesImmunity, 2003
- The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunityTrends in Immunology, 2001
- Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditionsEuropean Journal of Immunology, 1997
- Prostaglandin E2 and Tumor Necrosis Factor α Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 ProductionJournal of Experimental Medicine, 1997
- Improved methods for the generation of dendritic cells from nonproliferating progenitors in human bloodJournal of Immunological Methods, 1996
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.Journal of Experimental Medicine, 1995
- Proliferating dendritic cell progenitors in human blood.Journal of Experimental Medicine, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- The distinct surface of human blood dendritic cells, as observed after an improved isolation method.Proceedings of the National Academy of Sciences, 1990